Hasten
Latest round
- Series A
Last raised
- Mar 2022
Total raised
- Undisclosed
Investors
- 3
About Hasten
Founded in 2020 and based in Hefei, China, Hasten is a biopharmaceutical company that focuses on the research and development of drugs in the field of chronic disease and age-related disease management. The company has offices in cities such as Beijing, Shanghai and Guangzhou. As of 2023, it has more than 700 employees. The company relies on the healthcare platform and resources of its shareholder, Kangqiao Capital, to enrich its product mix and product pipeline in the area of chronic disease and age-related disease management. The company's main products include Adenidine, Yidabi and Basexin, etc. Its products are used in areas such as cardiovascular and metabolism. The company also provides other services including pharmaceutical commissioning, pharmaceutical wholesaling, testing and inspection services, pharmaceutical import and export, and health food production and sales.
Who invested in Hasten
3 investors across 1 round
See all investors in Hasten
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 4, 2022
Amount
Undisclosed
Investors
Questions about Hasten
Who invested in Hasten?
Hasten has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hasten raised?
Hasten has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hasten last raise money?
Hasten's most recent round on record is a Series A, in Mar 2022.
What does Hasten do?
Founded in 2020 and based in Hefei, China, Hasten is a biopharmaceutical company that focuses on the research and development of drugs in the field of chronic disease and age-related disease management.
Where is Hasten headquartered?
Hasten is headquartered in Hefei, China.
Which VCs invest in companies like Hasten?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hasten's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Hasten? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.